* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download karnataka, bengaluru
Specialty drugs in the United States wikipedia , lookup
Orphan drug wikipedia , lookup
Psychopharmacology wikipedia , lookup
Neuropsychopharmacology wikipedia , lookup
Polysubstance dependence wikipedia , lookup
Compounding wikipedia , lookup
Drug design wikipedia , lookup
Pharmacogenomics wikipedia , lookup
Neuropharmacology wikipedia , lookup
Theralizumab wikipedia , lookup
Drug discovery wikipedia , lookup
Discovery and development of proton pump inhibitors wikipedia , lookup
Drug interaction wikipedia , lookup
Pharmaceutical industry wikipedia , lookup
Prescription costs wikipedia , lookup
Prescription drug prices in the United States wikipedia , lookup
Pharmacokinetics wikipedia , lookup
FORMULATION DESIGN AND EVALUATION OF CHEWABLE TABLETS CONTAINING H2 BLOCKER Synopsis for M.Pharm Dissertation submitted to the Rajiv Gandhi University of Health Sciences Karnataka, Bengaluru Submitted By Mr. Rahil M Patait 1st Year M.Pharm Under the guidance of Dr. Paranjothy KLK M.Pharm, Ph.D Professor & Head DEPARTMENT OF INDUSTRIAL PHARMACY ADITYA BENGALURU INSTITUTE OF PHARMACY EDUCATION AND RESEARCH KOGILU MAIN ROAD, YALAHANKA, BENGALURU-64 2012-13 RAJIV GANDHI UNIVERSITY OF HEALTH SCIENCES, KARNATAKA, BENGALURU ANNEXURE II PROFORMA FOR REGISTRATION OF SUBJECTS FOR DISSERTATION 1. NAME OF THE CANDIDATE Mr. Rahil M Patait AND ADDRESS (IN BLOCK Present Address LETTERS) Aditya Bengaluru Institute of Pharmacy Education and Research (ABIPER), Behind Annapurneswari Temple, Kogilu Main road, Yelahanka, Bengaluru-64, Karnataka. 2. NAME OF THE INSTITUTION ADITYA BANGLORE INSTITUTE PHARMACY EDUCATION AND RESEARCH 3. COURSE OF STUDY AND SUBJECT MASTER OF PHARMACY IN INDUSTRIAL PHARMACY. 4. DATE OF ADMISSION OF COURSE 5. TITLE OF TOPIC 23/09/2013 FORMULATION DESIGN AND EVALUATION OF CHEWABLE TABLETS CONTAINING H2 BLOCKER OF 6. BRIEF RESUME OF THE INTENDED WORK 6.1 Need for the study : The goal of any drug delivery system is to provide a therapeutic amount of drug to the proper site of the body, to achieve promptly and then maintain the desired therapeutic drug concentration that elicits the desired pharmacological action and to minimize the incidence and the severity of unwanted adverse effects.1 For many decades, treatment of an acute disease or a chronic illness has been mostly accomplished by delivering drugs using various pharmaceutical dosage forms, including tablets, capsules, pills, suppositories, ointments, creams, liquids, aerosols, and injectables as carriers. Amongst various routes of drug delivery, oral route is perhaps the most preferred to the patients.2 The oral route of drug administration is the most important method of administering drugs for systemic effects. Nevertheless, it is probable that at least 90% of all drugs used to produce systemic effects are administered by oral route. It is the very popular and successfully used for delivery of drugs because of convenience and ease of administration, greater flexibility in dosage form design, and ease of production and low cost of such a system.3 Chewable tablets are intend to be chewed in the mouth prior to swallowing and are not intended to be swallowed intact. The purpose of chewable tablet is to provide a unit dosage form of medication which can be easily administered to children or to the elderly, who may have problem in swallowing a tablet intact. It is also recommended to achieve rapid onset of action. Chewable tablets are preferred for the drugs having high dose, the tablets of which cannot be swallowed. Dose of most of the antacids is large, so that the typical antacid tablet would be too large to swallow. The activity of antacid is related to its particle size. If the tablet is chewed prior to swallowing, better acid neutralization may be possible from a given antacid dose.4 A survey of the literature indicates that extensive work was conducted in the development of chewable tablet. The drugs studied are aluminium hydroxide, acetaminophen, antibiotics, and caffeine.5 The proposed ranitidine HCl chewable tablets contain ranitidine HCl which acts as an anti ulcer agent and it also contains calcium carbonate and magnesium hydroxide which act as antacids. A disintegrant such as microcrystalline cellulose may be added to give the patient the option of dispersing the tablet in water. It is made possible because of water solubility of ranitidine HCl. Ranitidine hydrochloride is a H2-receptor antagonist and is widely used. Ranitidine HCl is a white to pale yellow crystalline solid with melting point 70oC and is freely soluble in water, where as calcium carbonate and magnesium hydroxide are insoluble in water. Chemically ranitidine HCl is 1,1-ethenediamine, N-[2-[[[5-[(dimethylamino) methyl]-2-furanyl] mehyl]thio]ethyl]-N1-methyl-2-nitro, HCl. It is widely prescribed in active duodenal ulcers, gastric ulcers, Zollinger-Ellison syndrome, gastro esophageal reflux disease, and erosive esophagitis. The recommended adult oral dosage of ranitidine is 150 mg twice daily or 300 mg once daily. The effective treatment of erosive esophagitis requires administration of 150 mg of ranitidine 4 times a day.6 A conventional dose of 150 mg can inhibit gastric acid secretion up to 5 hours.7 Ranitidine is absorbed only in the initial part of the small intestine and has 50% absolute bioavailability. The half life is 2.5 to 3 hrs.8 Hence chewable tablets provide a safe and rapid onset of action, the proposed project play vital role in the above mentioned criteria. 6.2 Review of the literature : Chewable tablet dosage forms continued to draw attention in the search for improved patient compliance and decreased incidence of adverse drug reaction. Many drugs exhibit bitter taste when orally administered and the bitter taste often causes non-compliance of patients because of the discomfort. Therefore, suppression of the bitter taste has been an important subject for chewable tablets with simultaneous improvement in oral feeling. Swati J et al., designed and evaluated chewable tablet of levamisole (used in treatment of worm infestations). As an anthelmintic, it probably works by targeting the nematode nicotinergic acetylcholine receptor. In the market, levamisole tablets are available in the form of tablets. The chewable tablets of levamisole were prepared by using lactose or mannitol along with sodium starch glycolate in concentration ratios especially for paediatric use. Sodium saccharin and vanilla were used as sweetening agent and flavouring agent respectively. It was observed that the formulation containing lactose shows less disintegration time than formulation containing mannitol.9 Kanaka et al., formulated and evaluated montelukast sodium chewable tablets by different techniques. Montelukast sodium is used for prophylaxis and chronic treatment of asthma. Montelukast sodium chewable tablets (5 mg) were prepared and evaluated for the parameters such as average weight, hardness, tensile strength, friability, in vitro dissolution, and assay. The study on the dissolution profile revealed that product prepared from direct compression method had faster dissolution rate while compared to remaining batches and marketed product. Assay values were within the limits of 95 to 105%.10 Kathiresan K et al., formulated and evaluated 5 batches of loratadine chewable tablets. Loratadine, H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Results showed that thickness, weight variation, friability, hardness, and content uniformity of all 5 formulations were within the acceptance limits. But in the in-vitro dissolution study, formulations 1, 2, and 5 demonstrated better cumulative drug release than formulations 3 and 4. However, cumulative drug release of formulation 5 was comparable with innovator than formulations 1 and 2. Hence the study concludes that loratadine chewable tablet formulated using avicel CE 15 and starch paste showed better characteristics of chewable tablets.11 Hiroyuki S et al., developed oral acetaminophen chewable tablets with inhibited bitter taste. Various formulations with some matrix bases and coregents’ were examined for development of oral chewable tablets which suppressed the bitter taste of acetaminophen, often used as an antipyretic for infants. Corn starch/lactose, cacao butter and hard fat (Witepsol H-15) were used for matrix bases, and sucrose, cocoa powder and commercial bitter-masking powder mixture made from lecithin (Benecoat BMI-40) were used for corrigents against bitter taste. The bitter taste intensity was evaluated using volunteers by comparison of test samples with standard solutions containing quinine at various concentrations. For the tablets made of matrix base and drug, Witepsol H-15 best inhibited the bitter taste of the drug, and the bitter strength tended to be suppressed with increase in the Witepsol H-15 amount. When the inhibitory effect on the bitter taste of acetaminophen solution was compared among the corrigents, each tended to suppress the bitter taste; especially, Benecoat BMI-40 exhibited a more inhibitory effect. Further, chewable tablets were made of one matrix base and one corrigent, and of one matrix base and two kinds of corrigents, their bitter taste intensities after chewing were compared. As a result, the tablets made of Witepsol H-15/Benecoat BMI-40/sucrose, of Witepsol H-15/cocoa powder/sucrose and of Witepsol H-15/sucrose best masked the bitter taste so that they were tolerable enough to chew and swallow. The dosage forms best masking bitter taste showed good release of the drug, indicating little change in bioavailability by masking.12 Maddi SS et al., designed sodium fluoride chewable tablets for dental caries. Chewable tablets containing low dosage fluoride content were prepared using two varities of celluloses and their in vitro parameters were evaluated. An eighteen month clinical trial revealed that both these formulations were effective in controlling the caries. However, ethyl cellulose is proved to be superior to methylcellulose as a controlled release matrix material in controlling caries. Thus this study recommends ethyl cellulose matrix tablets containing low fluoride content is an efficacious and cost effective drug device in controlling dental caries.13 6.2 Objectives of the study : The primary aim of the proposed project is to develop chewable oral dosage form containing H2 blocker.In order to fulfill the aim the following objectives have to be met: To carryout pre-formulation studies of a drug & compatibility studies of drug & excipients by suitable methods. 7.0 To prepare H2 Blocker chewable tablets using different organoleptic agents. To carry out in vitro dissolution studies. To optimize the formulation according to the needs To carry out stability studies on an optimized formulation as per ICH guidelines. MATERIALS AND METHODS 7.1 Source of data The physicochemical properties of drug will be collected from the national and international journals, HELINET, internet facilities, related articles, and standard books from library of the college. 7.2 Method of collection of data (Including sampling procedure, if any) a. To develop the spectrophotometric method for the estimation of H2 blocker in suitable pH solution. b. Preformulation studies including solubility, compatibility with the excipients. c. To evaluate the physical properties of powder blend of tablet batches such as particle size distribution, angle of repose, bulk density, compressibility index, etc. d. Evaluation of ranitidine hydrochloride chewable tablets for the parameters such as hardness, friability, dimensions, drug content, drug release, uniformity of weight, bitterness and sweet taste intensity etc. e. In vitro release characteristics of H2 blocker from the chewable tablets. f. Short term stability studies of prepared formulations as per ICH guidelines. i) Normal storage: 25°C ± 2°C/60% RH ± 5% RH ii) Accelerated conditions: 40°C ± 2°C/75% RH ± 5% RH iii) Stress testing is conducted on a single batch of the tablets. The study includes testing the effect of temperature at 50°C, 60°C, etc. and humidity at 75% RH or greater as the drug is heat sensitive. iv) Packing system; The stability studies will be conducted on the drug substance packaged in a container. v) Testing Frequency: Samples (n = 3) will be drawn every week and will be studied. 7.3 Does the study require any investigations or interventions to be Conducted on patients or other humans or animals? If so, please Describe in brief. Not applicable 7.4 Has ethical clearance been obtained from your institute in case 7.3? Not applicable. 8. LIST OF REFERENCES: 1. Darshsana DH, Mangal SN, Sudhakar DG. Design and evaluation of an extended release tablet of prochlorperazine maleate. Ind drugs 2001;38:69-74. 2. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. Int J Pharn 1995;125:91-7. 3. Herbert AL, Leon L, Joseph LK. The theory and practice of industrial pharmacy. 3rd ed. Bombay: Varghese Publishing House; 1991. p.134-48. 4. Herbert A, Libermann, Leon L. Pharmaceutical dosage forms tablets. New York: Marcel Dekker Inc; 1980. p. 298-337. 5. Howard CA, Nicholas GP, Loyd VA. Pharmaceutical dosage form and drug delivery system. 6th ed. New Delhi: B.I.Waverty Pvt Ltd; 1995. p. 230,655-8. 6. Somade S, Singh K. Comparative evaluation of wet granulation and direct compression methods for preparation of controlled release ranitidine HCl tablets. Indian J Pharm Sci 2002;64:285. 7. Lauritsen K. Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases. Clin Pharmacokinet 1990;19:94-125. 8. Grant S. Ranitidine an updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in peptic ulcer and other allied diseases. Drugs 1989;37:80170. 9. Swati J, Mahesh G, Dhaval B, Bhanudas K, Aniruddha C. Formulation and evaluation of chewable tablet of levamisole. Int J Res Pharm Sci 2010;1(3):282-9. 10. Kanaka DDN, Prameela RA, Radha MB, Sai MB. Formulation and evaluation of montelukast sodium chewable tablets. Int J Pharm sci Bio 2010;1(1):20-4. 11. Kathiresan K, Vijin P, Moorthi C, Manavalan R. formulation and evaluation of loratadine chewable tablets. Res J Pharm Bio Che Sci 2010;1(4):763-74. 12. Hiroyuki S, Hiraku O, Yuri T, Masanori I, Yoshiharu M. Development of oral acetaminophen chewable tablets with inhibited bitter taste. Int J Pharma 2003;251(12):123-32. 13. Maddi SS, Tandon S, Aithal KS. Clinical evaluation of sodium fluoride chewable tablets in dental caries. Indian J Dent Res 1999;10(4):146-9. 14. http://www.druglib.com/druginfo/ranitidine/description_pharmacology/4/12/2010. 9. NAME AND SIGNATURE OF THE CANDIDTE (Rahil M Patait) 10. REMARKS OF THE GUIDE 11.1 NAME OF THE GUIDE RECOMMENDED AND FORWARDED Dr. Paranjothy KLK HOD, DEPT. OF IND. PHARMACY ABIPER, BENGALURU-64 11.2 SIGNATURE OF GUIDE 11.3 CO-GUIDE NOT APPLICABLE 11.4 HEAD OF THE DEPARTMENT Dr. Paranjothy KLK HOD, DEPT. OF IND. PHARMACY ABIPER, BENGALURU-64 11.5 SIGNATURE OF HOD 12.1 REMARKS OF THE PRINCIPAL RECOMMENDED AND FORWARDED Prof. A K Gnanachandran 12.2 PRINCIPAL PRINCIPAL ABIPER, BENGALURU-64 12.3 SIGNATURE OF THE PRINCIPAL